Would you use OncoType in a postmenopausal female with HR+/HER2- with LN involvement who clinically meets RxPONDER criteria of 1-3 LN to guide the use of neoadjuvant chemotherapy?

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

How would the use of Oncotype guide your management in the neoadjuvant setting?

Answer from: Medical Oncologist at Academic Institution

Yes. If I am asked to consider neoadjuvant therapy in a postmenopausal woman with an ER/PR+, HER2 negative cancer, who is otherwise a candidate for chemotherapy, I will start the endocrine therapy and send OncotypeDX to make sure that we are not leaving out an important part of her management, i.e. ...

Comments

Medical Oncologist at Upper Chesapeake Hematology Oncology
In practice, how often have you found neoadjuvant ...

Answer from: Medical Oncologist at Community Practice

I am not sure if I would. Having seen unimpressive results on my patients I've enrolled on ALTERNATE trial and the unimpressive preliminary results of the ALTERNATE trial, I believe neoadjuvant approach is not as promising as it is in HER-2 positive or triple negative breast cancer setting. ALTERNA...

Related Questions